CLL expressed significantly lower levels of CDK9 compared to normal donors (Figure 4A), suggesting a potential therapeutic index between these tumor cells and normal cells if targeting this is the predominate mechanism of action. This evidence concerns the gene CDK9 and B-cell chronic lymphocytic leukemia.